Disclosure Statement. Learning Objectives. American Psychiatric Nurses Association. Christian J. Teter, PharmD, BCPP 1 BUPRENORPHINE UPDATE
|
|
- Anabel Goodman
- 5 years ago
- Views:
Transcription
1 BUPRENORPHINE UPDATE Christian J. Teter, Pharm.D., BCPP Associate Professor, Psychopharmacology College Of Pharmacy, University Of New England Portland, ME Image Source: pubchem.ncbi.nlm.nih.gov Disclosure Statement This speaker has no conflict of interest to disclose. There will be no off label drug use discussed in this presentation. Learning Objectives 1. Differentiate between signs and symptoms of opioid intoxication as compared to opioid withdrawal. 2. List the potential advantages of buprenorphine treatment as compared to methadone treatment. 3. Recommend the appropriate therapeutic monitoring required upon the initiation of buprenorphine treatment. 4. Identify medications that should be avoided or used with caution when taken concomitantly with buprenorphine. Christian J. Teter, PharmD, BCPP 1
2 Abbreviations 4 ADME = absorption, distribution, metabolism, elimination OUD = opioid use disorder PD = pharmacodynamics PK = pharmacokinetics SAMHSA = Substance Abuse and Mental Health Association SUD = substance use disorder Buprenorphine: A Guide for Nurses 5 SAMHSA (key resource) Public domain; FREE; PDF available for download Introduction Drug Addiction Treatment Act of 2000 (DATA 2000) Office-based treatment for OUDs Schedule III-V FDA-approved medications Expanded access to OUD treatment Focus of this lecture is on the clinical use of buprenorphine medications Clinicians must always refer to state and federal laws in regards to appropriate buprenorphine use Christian J. Teter, PharmD, BCPP 2
3 Opioid Pharmacology Primer Opioid receptor types Mu opioid receptor (MOR) Kappa opioid receptor (KOR) Delta opioid receptor (DOR) Opioid receptor activity Agonists Antagonists Partial agonists Basic opioid pharmacology Affinity Intrinsic activity Dissociation Buprenorphine possesses slow dissociation rate Long duration of action Unpredictable reversal with opioid antagonists Comparatively less physical dependence Full Opioid Agonists Bind to and activate receptor site As dose is increased, effect is increased until maximum response is attained Examples: Heroin Oxycodone Methadone Opioid Antagonists Bind to the receptor without causing activity An antagonist can block the receptor from being activated by partial or full agonist Examples: Naloxone Naltrexone Christian J. Teter, PharmD, BCPP 3
4 Partial Opioid Agonists Bind to and activate the receptor Activity reaches plateau at which an increase in dose does not result in increased activity Examples: Buprenorphine Pentazocine Buprenorphine Pharmacology High-affinity partial mu opioid agonist Competes with other opioids Slow dissociation Long duration of action Unpredictable reversal Ceiling effect May lower abuse liability Safer in overdose Limit efficacy (?) ceiling effect Buprenorphine Pharmacokinetics (PK) 12 Absorption Distribution Metabolism Elimination Route of administration impacts ADME Christian J. Teter, PharmD, BCPP 4
5 Buprenorphine PK Pharmaceutical delivery system Sublingual buprenorphine = good bioavailability Sublingual naloxone = low bioavailability Oral buprenorphine and naloxone = poor (gastro-intestinal) bioavailability Injection Naloxone precipitates opioid withdrawal Deter abuse via this route of administration APPROPRIATE USE Growing Number and Variety of Buprenorphine/naloxone Formulations Sublingual Tablets Various strengths Sublingual Film Various strengths Buccal Film Various strengths Image source: Suboxone Sublingual Film NOTE: patient education very important! Buprenorphine PK Absorption Oral (poor); sublingual (fair) C max and AUC linear (4 to 16 mg) **Formulation-specific administration instructions must be closely followed for adequate absorption** Distribution Highly protein bound ( 96%) Alpha and beta globulin Christian J. Teter, PharmD, BCPP 5
6 Metabolism Buprenorphine PK N-dealkylation to norbuprenorphine (active metabolite) via cytochrome P450 3A4 Glucuronidation Elimination Buprenorphine and norbuprenorphine found in urine (30%) and feces (69%) Elimination half-life from plasma = hours* Longer due to slow dissociation rate Buprenorphine Drug-drug Interactions Cytochrome P450 3A4 Inhibitors (examples): Azole antifungals Macrolide antibiotics HIV protease inhibitors Grapefruit juice Inducers (limited data) CNS depressants Reports of death when combined with benzodiazepines Opioids May precipitate withdrawal Full opioid agonist Depends upon baseline opioid status Drug-drug Interactions (examples) 18 Buprenorphine Atazanavir Combination of buprenorphine + atazanavir (without ritonavir) results in both lower atazanavir levels and greater buprenorphine exposure; AVOID this bidirectional-interacting drug combination Conivaptan Conivaptan is a potent inhibitor of CYP3A4; manufacturer recommends its use be avoided with medications metabolized by CYP3A4 CYP3A4 inhibitors (in addition to specific medications listed) May raise buprenorphine levels; monitor for greater than expected buprenorphine effects Christian J. Teter, PharmD, BCPP 6
7 Buprenorphine Clinical Overview Pharmacologic Tools for OUDs Opioid-specific (vs. adjunctive medications): Agonists Partial Agonists Antagonists Methadone Buprenorphine Naloxone Naltrexone Rationale for Opioid Agonist Treatment Prevents withdrawal Reduces craving Blocks or attenuates the high Decreases: Illicit opioid use Criminal activity Sexually transmitted diseases Christian J. Teter, PharmD, BCPP 7
8 Titrate to Stability Intoxication Withdrawal Withdrawal Intoxication Insufficient Opioid Excessive Opioid Withdrawal Intoxication Stabilization Signs of Opioid Intoxication and Overdose Opioid Intoxication Conscious Sedated, drowsy Slurred speech Nodding or intermittently dozing Memory impairment Mood normal to euphoric Pupillary constriction Opioid Overdose Unconscious Pinpoint pupils Slow, shallow respirations (e.g., below 10 breaths per minute) Pulse rate slow (e.g., below 40 beats per minute) Overdose triad: apnea, coma, pinpoint pupils (with terminal anoxia: fixed and dilated pupils) Opioid Withdrawal Symptoms Stage Grade Physical Signs/Symptoms Early Withdrawal (8 24 hours after last use) Fully Developed Withdrawal (1 3 days after last use) Grade 1 Grade 2 Grade 3 Grade 4 Lacrimation and/or rhinorrhea Diaphoresis Yawning, restlessness, insomnia Dilated pupils Piloerection Muscle twitching, myalgia and arthralgia Abdominal pain Tachycardia, tachypnea Hypertension Fever Anorexia or nausea Extreme restlessness Diarrhea and/or vomiting Dehydration Hyperglycemia Hypotension Curled-up (fetal) position Christian J. Teter, PharmD, BCPP 8
9 Buprenorphine Efficacy Multiple trials have confirmed the efficacy of buprenorphine for opioid agonist treatment Retention in treatment Thrice-weekly negative urines Please see Treatment Guidelines (next slide) Over a range of doses: Target dose 12 to 16 mg/day Little added benefit of buprenorphine doses > 32 mg (ceiling effect) Treatment Guidelines for Opioid Use Disorders 26 Level of American Psychiatric Association Intervention (APA) Treatment Guidelines (2006) First-line Opioid intoxication/overdose: naloxone British Association of Psychopharmacology (2012) Opioid intoxication/overdose: not included in review Second-line Opioid Withdrawal: buprenorphine or methadone Opioid Dependence: buprenorphine or methadone Opioid Withdrawal: clonidine Opioid Dependence: naltrexone Opioid Withdrawal: alpha-2-adrenergic agonists or buprenorphine or methadone (using tapered doses) Opioid Dependence: buprenorphine or methadone Opioid Withdrawal: slow release oral morphine (SROM) Opioid Dependence: naltrexone Source: Teter CJ. Substance Use Disorders Board Certified Psychiatric Pharmacist (BCPP) Examination Review and Recertification Course. College of Psychiatric & Neurologic Pharmacists: Lincoln (NE); Treatment Phases Induction Medically monitored Stabilization Dose adjustments Maintenance Indefinite Health care professionals in the community likely to become involved at this point in treatment. Christian J. Teter, PharmD, BCPP 9
10 Sample Regimen for Buprenorphine Induction Treatment of Opioid Withdrawal and Long-Term Relapse Prevention 28 Day Buprenorphine Sublingual/buccal Dosage 1 2 mg every 2 hours (maximum, 8 mg on first day) 2 Start with total dose of day 1 with additional 2 4 mg every 2 hours (maximum, 16 mg) 3+ Start with total dose of day 2, with additional 2 4 mg every 2 hours (maximum, 32 mg) 4 5 Maintain on dose required to alleviate withdrawal symptoms (a) (a) Patient will likely be transitioned to long-term maintenance dose indefinitely. Data from Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication no. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration; Buprenorphine Side Effects Due to direct opioid effects or signs and symptoms of (potentially-induced) withdrawal: - Headache - Constipation - Pain (abdominal) - Nausea & vomiting - Insomnia - Anxiety - Diaphoresis - Depression Patient Education Example (essential!) KEY: formulationspecific administration must be followed; patient education! Image source: dailymed.nlm.nih.gov 30 Christian J. Teter, PharmD, BCPP 10
11 Theoretical Advantages of Methadone vs. Buprenorphine Treatment Access Abuse Potential Adverse Events Medication Cost Drug Interactions Efficacy* Serious toxicity (e.g., respiratory depression) Methadone (full agonist) Advantage Advantage (severe dependence) Buprenorphine (partial agonist) Advantage Advantage Advantage Advantage Advantage *Methadone and Buprenorphine are both considered first-line, effective medications for the treatment of opioid use disorders. There may be an advantage for methadone among patients with severe opioid dependence given its full opioid agonist properties. Source: Teter CJ. Substance Use Disorders Board Certified Psychiatric Pharmacist (BCPP) Examination Review and Recertification Course. College of Psychiatric & Neurologic Pharmacists: Lincoln (NE); Special Populations (pregnancy and lactation) Pregnancy Methadone remains the standard of care (e.g., long history of use in many patients) Opioid antagonists should be AVOIDED in pregnant women (risk of inducing withdrawal in mother and fetus) AVOID any combination [buprenorphine/naloxone] product Breast feeding Poor oral buprenorphine/naloxone absorption Baby should be exposed to low levels of medication Special Populations (age-related considerations) Children Clinician must be familiar with state-level laws in regards to parental consent for treatment Elderly Careful consideration of possible pharmacokinetic and pharmacodynamic changes must be taken into account Examples: Changes in body composition Changes in metabolic clearance Changes in renal clearance Other medications (i.e., interactions) Christian J. Teter, PharmD, BCPP 11
12 Special Populations (co-occurring conditions) Co-occurring Pain Higher doses of opioid agonists may be required to treat symptoms of pain Overcome buprenorphine partial agonist activity Careful assessment and monitoring required Dose adjustments as necessary Buprenorphine may not be optimal medication to treat an opioid use disorder in patients with co-occurring pain Full opioid agonist could be considered Careful assessment and monitoring required Special Populations (co-occurring conditions) Psychiatric Disorders Medications used to treat psychiatric disorders may interact with buprenorphine Example: Anxiety: benzodiazepines Likely AVOID buprenorphine in patients with acute psychiatric symptoms: Suicidality Acute psychosis Conclusions Christian J. Teter, PharmD, BCPP 12
13 Buprenorphine Advantages Efficacious (evidence that it works!) More severe patients may require a full opioid agonist Lower risk for abuse and diversion Not zero risk! Safer in overdose Ceiling effect Possibly less stigma than methadone Outpatient treatment Possibly greater access to opioid treatment Outpatient treatment Nurses/Pharmacist Roles Patient education on proper medication use **Key role for health care professionals, in regards to buprenorphine treatment** Various formulations and doses Unique administration instructions Medication adherence Historically poor among individuals with SUDs Side effects vs. withdrawal symptoms Drug interactions CYP3A4-based interactions Nurses/Pharmacist Roles Patient monitoring (key role for health care professionals) Substance use behaviors (broad scope) Includes: Treatment effectiveness Aberrant medication taking behaviors ( both discussed below) Medication-specific: Efficacy (e.g., no relapse; retention in treatment) Medication adherence Side effects (contrast with w/d symptoms) Drug interactions (particularly CYP3A4 mediated) Abuse, misuse, and/or diversion behaviors Laboratory monitoring Urine drug testing, liver function tests, renal function Christian J. Teter, PharmD, BCPP 13
14 Additional Information SAMHSA Resources (public domain) Primary website: Various website links for additional information PDFs available for download TAP 30 Center for Substance Abuse Treatment. Buprenorphine: A Guide for Nurses DHHS Pub. No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration. TIP 40 Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) Rockville, MD: Substance Abuse and Mental Health Services Administration, Additional Information Teter CJ. Substance Use Disorders Board Certified Psychiatric Pharmacist (BCPP) Examination Review and Recertification Course. College of Psychiatric & Neurologic Pharmacists: Lincoln (NE); Teter CJ. Substance-Related Disorders. Pharmacotherapy Principles and Practice, 3rd Edition. Editors: Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, and DiPiro JT. The McGraw-Hill Companies; Christian J. Teter, PharmD, BCPP 14
Substitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationLONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE
LONG TERM PHARMACOTHERAPY OF OPIOID DEPENDENCE DR. SHILPA ADARKAR ASSOCIATE PROFESSOR DEPARTMENT OF PSYCHIATRY & DRUG DEADDICTION CENTRE OF EXCELLENCE SETH GSMC & KEMH LONG TERM OPTIONS FULL AGONIST PARTIAL
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationBuprenorphine Access in California
Buprenorphine Access in California James J. Gasper, PharmD, BCPP Pharmacy Benefits Division Department of Health Care Services james.gasper@dhcs.ca.gov Source: CDPH Vital Statisitics Death Statistical
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationTreatment Alternatives for Substance Use Disorders
Treatment Alternatives for Substance Use Disorders Dean Drosnes, MD, FASAM Associate Medical Director Director, Chronic Pain and SUD Program Caron Treatment Centers 1 Disclosure The speaker has no conflict
More informationOpioids Research to Practice
Opioids Research to Practice CRIT/FIT 2016 April 2016 Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education
More informationOpioids Research to Practice
Opioids Research to Practice May 2013 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Case 32 yo female brought in after heroin overdose
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2010 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationMedications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?
Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They? Yngvild Olsen, MD, MPH Cecil County Board of Health Workgroup Meeting Elkton, MD October 8, 2013 Objectives
More informationGOALS AND OBJECTIVES
SUBOXONE AND VIVITROL: ARE THERE DISPARITIES SURFACING IN MEDICATION ASSISTED TREATMENTS? P R E S E N T E D B Y D R. K I AM E M AH A N I A H & D R. M Y E C H I A M I N T E R - J O R D AN GOALS AND OBJECTIVES
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationDeveloped and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services
Developed and Presented by Randall Webber, MPH, CADC JRW Behavioral Health Services www.randallwebber.com MAT clients are still addicted Truth: MAT clients will experience withdrawal symptoms if they stop
More informationOpioid dependence and buprenorphine treatment
Opioid dependence and buprenorphine treatment David Roll, MD Revere Family Health, Cambridge Health Alliance Instructor in Medicine, Harvard Medical School Joji Suzuki MD Medical Director of Addictions
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationOpioid Agonists. Natural derivatives of opium poppy - Opium - Morphine - Codeine
Natural derivatives of opium poppy - Opium - Morphine - Codeine Opioid Agonists Semi synthetics: Derived from chemicals in opium -Diacetylmorphine Heroin - Hydromorphone Synthetics - Oxycodone Propoxyphene
More informationOpioids. Sergio Hernandez, MD
Opioids Sergio Hernandez, MD Required Slide Disclosures 1. SIGNIFICANT FINANCIAL INTERESTS NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT 2. GENERAL AND OBLIGATION INTERESTS All general
More informationDr Alistair Dunn. General Practitioner Whangarei
Dr Alistair Dunn General Practitioner Whangarei 1982 Temgesic = Buprenorphine Sublingual opiate analgesic 0.2 mg Popular drug of abuse 1991 Temgesic NX = Bup & Nalxone Nalxone added to deter abuse 1999
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationOpioid dependence: Detoxification
Opioid dependence: Detoxification What is detoxification? A. Process of removal of toxins from the body? B. Admitting a drug dependent person in a hospital and giving him nutrition? C. Stopping drug use
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More information(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)
Buprenorphine Initiation and Maintenance in Pregnancy (Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines) Assessment The diagnosis of OUD should be confirmed by DSM-5
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationOAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM
OAT Transitions - focus on microdosing Mark McLean MD MSc FRCPC CISAM DABAM Disclosures No pharmaceutical industry or other financial conflicts of interest Study Physician for research funded by Canadian
More informationDr M H Mosaddegh Pharm D, PhD
Dr M H Mosaddegh Pharm D, PhD opioid All compounds related to opium Opium derived from opos, Greek word of juice, juice of opium poppy, Papaver somniferum Opiates Drugs derived from opium. Included the
More informationMEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID Punta Cana 2018
MEDICALLY ASSISTED TREATMENT IN PROBLEMATIC OPIOID USE @joelbordman Punta Cana 2018 Copyright 2017 by Sea Courses Inc All rights reserved. No part of this document may be reproduced, copied, stored, or
More informationBUPRENORPHINE. THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names
BUPRENORPHINE THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names Generic? Yes (not for with naloxone or implant) Class mu opioid receptor partial agonist
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationMETHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE
METHADONE TO BUPRENORPHINE TRANSFERS TRANSITIONING FROM METHADONE MAINTENANCE TO BUPRENORPHINE/NALOXONE Work with methadone clinic staff to coordinate the methadone taper, with the transition to buprenorphine/naloxone:
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationModule II Opioids 101 Opiate Opioid
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module II Opioids 101 Module II Goals of the Module This module reviews the following:! Opioid addiction and the brain!
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More information9/13/2017. Buprenorphine Treatment (Suboxone) Disclosures. We ve Got a Big Opioid Problem. Selahattin Kurter, MD Spectrum Healthcare
Buprenorphine Treatment (Suboxone) Selahattin Kurter, MD Spectrum Healthcare Board Certified in Psychiatry and Addiction Medicine Disclosures No financial reimbursement for this lecture Consultant for
More informationAnalgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I. Mr.D.Raju,M.pharm, Lecturer
Analgesic Drugs PHL-358-PHARMACOLOGY AND THERAPEUTICS-I Mr.D.Raju,M.pharm, Lecturer Mechanisms of Pain and Nociception Nociception is the mechanism whereby noxious peripheral stimuli are transmitted to
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationClinical Policy: Lofexidine (Lucemyra) Reference Number: ERX.NPA.88 Effective Date:
Clinical Policy: (Lucemyra) Reference Number: ERX.NPA.88 Effective Date: 07.31.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationOptimizing Opioid Dependence Treatment A Guideline for Pharmacists
Optimizing Opioid Dependence Treatment A Guideline for Pharmacists Module 3: Optimal Use of Methadone F e b r u a r y 2 0 1 5 Learning Objectives To know and understand the pathophysiology of substance
More informationImplementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018
Implementing Buprenorphine Treatment in Opioid Treatment Programs Webinar 2, October 3, 2018 Judith Martin, MD, Medical Director of Substance Use Services, San Francisco Department of Public Health Webinar
More informationBuprenorphine/Naloxone
ADIS DRUG EVALUATION Drugs 2009; 69 (5): 577-607 0012-6667/09/0005-0577/$55.55/0 ª 2009 Adis Data Information BV. All rights reserved. Buprenorphine/Naloxone A Review of its Use in the Treatment of Opioid
More informationBuprenorphine pharmacology
Buprenorphine pharmacology Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Opioids full, partial, antagonist Full Agonists - bind completely
More informationPharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco
Pharmacotherapy for opioid addiction Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco Disclosure slide No commercial conflicts to disclose. Gaps in current treatment of opioid
More informationMethadone Maintenance
Methadone Maintenance A Practical Guide to Pharmacotherapy Methadone/Buprenorphine 101 Workshop, April 1, 2017 Ron Joe, MD, DABAM Objectives I. Pharmacology Of Methadone II. Practical Application of Pharmacology
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationThe safety concerns defined with the reference product apply to Buprenorphine-Naloxone 2/0.5 mg, 8/2 mg, sublingual tablets.
These products are indicated in the substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationTo Dream The Impossible Dream: Acute Pain Management for Patients on Buprenorphine
To Dream The Impossible Dream: Acute Pain Management for Patients on Buprenorphine Tanya J. Uritsky, PharmD, BCPS, CPE Disclosure Nothing to disclose 1 Learning Objectives Describe how the pharmacokinetic
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationBuprenorphine for Family Medicine. Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17
+ Buprenorphine for Family Medicine Hannah Snyder, MD Addiction Medicine Fellow, UCSF 12/7/17 + Disclosures No conflicts of interest Off-label use of medications + Who here: Has taken care of a patient
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationConsequences and Treatment of Opioid Abuse During Pregnancy. Katie Ellis, PharmD March 12, 2018
Consequences and Treatment of Opioid Abuse During Pregnancy Katie Ellis, PharmD March 12, 2018 Disclosure I have nothing to disclose. Objectives At the completion of this activity, the pharmacist will
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationFentanyls and Naloxone. Opioids, Overdose, and Naloxone
Opioids, Overdose, and Naloxone Presenter Disclosure Presenter s Name: Michael Beazely I have no current or past relationships with commercial entities Speaking Fees for current program: I have received
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationPART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018
PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018 TAPERING OPIOIDS GETTING STARTED ON OPIOIDS IS EASY BUT GETTING PATIENTS OFF IS HARD WE ARE ARE OBLIGED TO TAPER PATIENTS DOWN AND OFF OPIOIDS
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationRelapsing Late in Life: Opioid use disorder in a geriatric patient
Relapsing Late in Life: Opioid use disorder in a geriatric patient Kerry Sheets, MD Geriatric Medicine Fellow, HCMC MAGIC Annual Conference, 11/9/2018 Outline Case presentation Epidemiology of opioid use/misuse
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationModule Two: Pharmacotherapies for Opioid Substitution Treatment
Module Two: Pharmacotherapies for Opioid Substitution Treatment Neurobiology of Addiction Pharmacology of Opioids Methadone Buprenorphine Pharmacokinetics of Methadone & Buprenorphine Opioid effects Intoxication
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationWITHDRAWING FROM BUPRENORPHINE THERAPY
WITHDRAWING FROM BUPRENORPHINE THERAPY VARIOUS REASONS TO STOP BUPRENORPHINE pregnancy and lactation emergency surgery/elective surgery difficult to manage side effects of buprenorphine patients showing
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationQuick Guide. For Physicians. Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Quick Guide For Physicians Based on TIP 40 Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Buprenorphine Clinical Guide Contents Why a Quick Guide?....................
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationMAT - ICAAD 2018 Ron Jackson, MSW, LICSW
The ATTC Network Ten Regional Centers northwest@attcnetwork.org www.attcnetwork.org/northwest phone. 206-685-4419 1107 NE 45 th St, Ste 120, Seattle, WA 98105 http://attcnetwork.org/northwest U.S. Opioid
More informationNALTREXONE DAVID CRABTREE, MD, MPH UNIVERSITY OF UTAH HEALTH, 2018
NALTREXONE DAVID CRABTREE, MD, MPH TREATMENT OF OPIOID USE DISORDER (OUD) Majority of people who develop OUD are not receiving treatment Only a small fraction of patients are offered treatment with medications
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationOpioid Use Disorders &Medication Treatment
Agency medical director comments Opioid Use Disorders &Medication Treatment Charissa Fotinos, MD, MSc Deputy Chief Medical Officer Washington State Health Care Authority Learning Objectives: 1) Review
More informationMethadone and Naltrexone ER
Methadone and Naltrexone ER Laura G. Kehoe, MD, MPH, FASAM Medical Director MGH Substance Use Disorder Bridge Clinic Assistant Professor of Medicine Harvard Medical School Disclosures Neither I nor my
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationTreatment of Opioid Use Disorder
Treatment of Opioid Use Disorder Casia Horseman, MD Assistant Professor Department of Psychiatry and Behavioral Health The Ohio State University Wexner Medical Center Objectives Discuss the historical
More informationMAT IN PREGNANCY KAYLA LIFE STAGE 1: ADOLESCENCE LIFE STAGE 2: EARLY ADULTHOOD. family History of addiction. addiction to oral opioids
MAT IN PREGNANCY R. COREY WALLER MD, MS PRINCIPAL, HEALTH MANAGEMENT ASSOCIATES FACULTY, INSTITUTE FOR HEALTHCARE INNOVATION (IHI) CHAIR, LEGISLATIVE ADVOCACY COMMITTEE, ASAM KAYLA LIFE STAGE 1: ADOLESCENCE
More informationProtocol For: Personally Furnishing Naloxone. Update Log
Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County
More informationPharmacology of Buprenorphine & Other Opioids Table of Contents
Pharmacology of Buprenorphine & Other Opioids Table of Contents...1 Goal:... 1 After completing this module participants will be able to:...1 Professional Practice Gaps...1 Module Introduction... 2 Case
More informationMEDICATION ASSISTED TREATMENT
MEDICATION ASSISTED TREATMENT MODULE 14 ALLIED TRADES ASSISTANCE PROGRAM PREVENTATIVE EDUCATION: SUBSTANCE USE DISORDER Medication Assisted Treatment Types of Medication Assisted Treatment: Methadone Naltrexone
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More information12/14/2018. Disclosures. Buprenorphine. Drug-Receptor Interactions. Affinity
ECHO Ontario Chronic Pain Bootcamp OPIOID CHALLENGE Buprenorphine/Naloxone: What and How? Friday, December 7, 2018 Disclosures Presenters: John Flannery & Andrew Smith Conflicts of Interest: None John
More informationOpioids- Indica-ons, Equivalence, Dependence and Withdrawal Methadone Maintenance (OST) Paul Glue
Opioids- Indica-ons, Equivalence, Dependence and Withdrawal Methadone Maintenance (OST) Paul Glue Scope Pharmacology of Opioids Equivalence Dependence and Withdrawal Methadone Maintenance (OST) 3 Opioid
More informationOpioid Use Disorders as a Brain Disease Why MAT is so important. Ron Jackson, M.S.W., L.I.C.S.W.
Opioid Use Disorders as a Brain Disease Why MAT is so important Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Organization Name: CareOregon Course Title:
More information6/6/2018. Nalbuphine: Analgesic with a Niche. Mellar P Davis MD FCCP FAAHPM. Summary of Advantages. Summary of Advantages
Nalbuphine: Analgesic with a Niche Mellar P Davis MD FCCP FAAHPM 1 Summary of Advantages Safe in renal failure- fecal excretion Analgesia equal to morphine with fewer side effects Reduced constipation
More informationUSE OF BUPRENORPHINE FOR CHRONIC PAIN
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences USE OF BUPRENORPHINE FOR CHRONIC PAIN MARK SULLIVAN, MD, PHD PSYCHIATRY AND BEHAVIORAL SCIENCES ANESTHESIOLOGY AND
More informationOpioids. October 29, Addiction Medicine Review Course CSAM, Newport Beach, CA
Opioids October 29, 2010 Addiction Medicine Review Course CSAM, Newport Beach, CA Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Boston University School of Medicine Boston Medical
More informationMedication Assisted Treatment. MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment
Medication Assisted Treatment MAT Opioid dependence/addiction Opioid treatment programs OTP Regulation of OTP Office Based Treatment Opioid Drugs Opium Morphine Heroin Codeine Oxycodone Roxycodone Oxycontin
More informationOPIOID REPLACEMANT THERAPY: AN OVERVIEW
OPIOID REPLACEMANT THERAPY: AN OVERVIEW Matthew Felgus MD FASAM Matthew A Felgus, MD, FASAM mafelgus@wisc.edu matthewfelgusmd.com 6333 Odana Rd, Ste 3, Madison WI 53719 (608) 257-1581 Board Certified in
More informationArizona s Opioid Epidemic
Arizona s Opioid Epidemic Rise in Heroin Addiction and the Dangers of Fentanyl Sara Salek, MD Chief Medical Officer Shana Malone, MS Clinical Initiatives Project Manager 1 Disclosures None The National
More informationMedication Assisted Treatment for Opioid Use Disorders and Veteran Populations
Medication Assisted Treatment for Opioid Use Disorders and Veteran Populations Kamala Greene Genece, Ph.D. VP, Clinical Director Phoenix Houses of New York Benjamin R. Nordstrom, M.D., Ph.D. President
More informationMedication Assisted Treatment. Michael Palladini, RPh MBA CAC
Medication Assisted Treatment Michael Palladini, RPh MBA CAC palladini.michael@gmail.com History of MAT Addiction as a Disease The concept of addiction as a disease of the brain challenges deeply ingrained
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lucemyra) Reference Number: CP.PMN.152 Effective Date: 07.31.18 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationQuestions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant:
Questions & Answers About Probuphine Here are the answers to some questions you may have about the Probuphine implant: 1. Can my doctor prescribe and insert Probuphine? 2. What should I do after the Probuphine
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationSafe Practices and Action Items
Safe Practices and Action Items Karen F Marlowe, Pharm D, BCPS Certified Pain Educator Auburn University Harrison School of Pharmacy University of South Alabama School of Medicine Case Study A 58 year
More informationOpioid Replacement Therapy
Opioid Replacement Therapy Matthew A. Felgus, MD mafelgus@wisc.edu 6333 Odana Rd, Suite 3, Madison, WI 53719 (608) 257-1581 Board Certified in Addiction Medicine Board Certified in Psychiatry matthewfelgusmd.com
More information